These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23046320)

  • 21. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial.
    Tepe G; Schnorr B; Albrecht T; Brechtel K; Claussen CD; Scheller B; Speck U; Zeller T
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):102-8. PubMed ID: 25616822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions.
    Zeller T; Brechtel K; Meyer DR; Noory E; Beschorner U; Albrecht T
    J Endovasc Ther; 2020 Oct; 27(5):683-690. PubMed ID: 32666871
    [No Abstract]   [Full Text] [Related]  

  • 23. Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
    Reijnen MMPJ; van Wijck I; Zeller T; Micari A; Veroux P; Keirse K; Lee SW; Li P; Voulgaraki D; Holewijn S
    J Endovasc Ther; 2019 Jun; 26(3):305-315. PubMed ID: 30931726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease.
    Jongsma H; Bekken JA; de Vries JP; Verhagen HJ; Fioole B
    J Vasc Surg; 2016 Nov; 64(5):1503-1514. PubMed ID: 27478005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
    Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
    Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Mid-Term Clinical Follow-Up Using Drug-Eluting Balloons on Tibial Artery "De Novo" Lesions in Patients With Critical Limb Ischemia: A Cohort Study.
    Tolva V; Casana R; Huibers A; Parati G; Bianchi P; Cireni L; Ferrero E; Halliday A
    Vasc Endovascular Surg; 2016 Jul; 50(5):304-8. PubMed ID: 27206745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial.
    Zeller T; Baumgartner I; Scheinert D; Brodmann M; Bosiers M; Micari A; Peeters P; Vermassen F; Landini M;
    Trials; 2014 Feb; 15():63. PubMed ID: 24552184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
    Katsanos K; Spiliopoulos S; Paraskevopoulos I; Diamantopoulos A; Karnabatidis D
    J Endovasc Ther; 2016 Apr; 23(2):356-70. PubMed ID: 26823485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
    Scheinert D; Schulte KL; Zeller T; Lammer J; Tepe G
    J Endovasc Ther; 2015 Feb; 22(1):14-21. PubMed ID: 25775674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
    J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T;
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
    Ott I; Cassese S; Groha P; Steppich B; Voll F; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Wittmann T; Kasel AM; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28743787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-Eluting vs Standard Balloon Angioplasty for Iliac Stent Restenosis: Midterm Results.
    Stahlhoff S; Donas KP; Torsello G; Osada N; Herten M
    J Endovasc Ther; 2015 Jun; 22(3):314-8. PubMed ID: 25991767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-eluting balloons and uncoated balloons perform equally to rescue infrainguinal autologous bypasses at risk.
    Jongsma H; Akkersdijk GP; de Smet AAEA; Vroegindeweij D; de Vries JPM; Fioole B
    J Vasc Surg; 2017 Aug; 66(2):454-460. PubMed ID: 28478021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions.
    Pecoraro F; Dinoto E; Pakeliani D; Mirabella D; Ferlito F; Bajardi G
    Ann Vasc Surg; 2021 Oct; 76():370-377. PubMed ID: 33951533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study.
    Gandini R; Del Giudice C; Merolla S; Morosetti D; Pampana E; Simonetti G
    J Endovasc Ther; 2013 Dec; 20(6):805-14. PubMed ID: 24325697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.